AstraZeneca and its partner Bristol-Myers Squibb have been granted marketing authorisation by the European Commission for Xigduo, its treatment of type 2 diabetes in the European Union.
It is the first regulatory approval for a fixed dose combination treatment of its kind. The product is for use in over-18s with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control.
The treatment inhibits SGLT2, a sodium-glucose cotransporter found predominantly in the kidney that is responsible for the majority of glucose reabsorption. In patients with type 2 diabetes, the capacity of the kidney to reabsorb glucose is increased by approximately 20%, further exacerbating the hyperglycaemia associated with the disease.
Elisabeth Björk, Vice President of Head of Late Phase Cardiovascular and Metabolic Development at AstraZeneca, said: ‘Xigduo is an important addition to the range of medicines to help patients manage glycaemic control. We recognise that not all patients are alike and that different treatments are needed, supporting a more personalised approach to disease management.
‘Metformin has long been a standard of diabetes care, and with the Xigduo approval, we now have an SGLT2 inhibitor and metformin combination product representing an innovative option for treating adults with type 2 diabetes.’
Source of information here.
Metformin out of patent which works, added to some new junk, jeez big pharma will come up with anything to make a quick buck. How about Zogomet. Metformin combined with fossilised bat dung, should be good for a $billion a year in sales.
Eddie
1 comment:
Do we really need this?
Post a Comment